Literature DB >> 21241810

Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.

Tim Chan1, Robert H Wiltrout, Jonathan M Weiss.   

Abstract

The liver is an immunologically unique organ, consisting of resident hematopoietic and parenchymal cells which often contribute to a relatively tolerant microenvironment. It is also becoming increasingly clear that tumor-induced immunosuppression occurs via many of the same cellular mechanisms which contribute to the tolerogenic liver microenvironment. Myeloid cells, consisting of dendritic cells (DC), macrophages and myeloid derived suppressor cells (MDSC), have been implicated in providing a tolerogenic liver environment and immune dysfunction within the tumor microenvironment which can favor tumor progression. As we increase our understanding of the biological mechanisms involved for each phenotypic and/or functionally distinct leukocyte subset, immunotherapeutic strategies can be developed to overcome the inherent barriers to the development of improved strategies for the treatment of liver disease and tumors. In this review, we discuss the principal myeloid cell-based contributions to immunosuppression that are shared between the liver and tumor microenvironments. We further highlight immune-based strategies shown to modulate immunoregulatory cells within each microenvironment and enhance anti-tumor responses. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21241810      PMCID: PMC3082592          DOI: 10.1016/j.intimp.2010.12.024

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  173 in total

1.  Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jon M Wigginton; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

2.  Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.

Authors:  Naoki Umemura; Masanao Saio; Tatsuhiko Suwa; Yusuke Kitoh; Juncheng Bai; Kenichi Nonaka; Guan-Feng Ouyang; Makoto Okada; Margit Balazs; Roza Adany; Toshiyuki Shibata; Tsuyoshi Takami
Journal:  J Leukoc Biol       Date:  2008-02-19       Impact factor: 4.962

Review 3.  Targeting immune suppressing myeloid-derived suppressor cells in oncology.

Authors:  Johnny Kao; Eric C Ko; Samuel Eisenstein; Andrew G Sikora; Shibo Fu; Shu-Hsia Chen
Journal:  Crit Rev Oncol Hematol       Date:  2010-03-20       Impact factor: 6.312

4.  Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors:  Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.

Authors:  Maria A Gonzalez-Carmona; Veronika Lukacs-Kornek; Anne Timmerman; Sara Shabani; Miroslaw Kornek; Annabelle Vogt; Yildiz Yildiz; Elisabeth Sievers; Ingo G H Schmidt-Wolf; Wolfgang H Caselmann; Tilman Sauerbruch; Volker Schmitz
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

6.  Transient local depletion of Foxp3+ regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death.

Authors:  Colin Reardon; Arthur Wang; Derek M McKay
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

7.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

Authors:  Bastian Hoechst; Lars A Ormandy; Matthias Ballmaier; Frank Lehner; Christine Krüger; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

8.  Role of Kupffer cells in the induction of tolerance of orthotopic liver transplantation in rats.

Authors:  Yong Chen; Zuojin Liu; Shaoyong Liang; Xiaofeng Luan; Feiwu Long; Jie Chen; Yong Peng; Lünan Yan; Jianping Gong
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

Review 9.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

10.  Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Authors:  James F Curtin; Marianela Candolfi; Tamer M Fakhouri; Chunyan Liu; Anderson Alden; Matthew Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

View more
  18 in total

1.  Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells.

Authors:  Rebecca K Martin; Sheinei J Saleem; Lauren Folgosa; Hannah B Zellner; Sheela R Damle; Giang-Kim T Nguyen; John J Ryan; Harry D Bear; Anne-Marie Irani; Daniel H Conrad
Journal:  J Leukoc Biol       Date:  2014-03-07       Impact factor: 4.962

2.  The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.

Authors:  Han Sang Kim; Chang Gon Kim; Jung Yong Hong; Il-Hwan Kim; Beodeul Kang; Sanghoon Jung; Chan Kim; Sang Joon Shin; Hye Jin Choi; Jaekyung Cheon; Hong Jae Chon; Ho Yeong Lim
Journal:  Ther Adv Med Oncol       Date:  2022-07-16       Impact factor: 5.485

3.  Freezing Fort Knox: Mesenteric Carcinoid Cryoablation.

Authors:  Erik Soule; Arya Bagherpour; Jerry Matteo
Journal:  Gastrointest Tumors       Date:  2017-08-31

4.  Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.

Authors:  Tim Chan; Timothy C Back; Jeffrey J Subleski; Jonathan M Weiss; John R Ortaldo; Robert H Wiltrout
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

5.  Patterns of metastasis in colon and rectal cancer.

Authors:  Matias Riihimäki; Akseli Hemminki; Jan Sundquist; Kari Hemminki
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

6.  Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Veronika Caisová; Andra Vieru; Zuzana Kumžáková; Simona Glaserová; Hana Husníková; Nikol Vácová; Gabriela Krejčová; Lucie Paďouková; Ivana Jochmanová; Katherine I Wolf; Jindřich Chmelař; Jan Kopecký; Jan Ženka
Journal:  BMC Cancer       Date:  2016-12-07       Impact factor: 4.430

7.  Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Authors:  Li-Chun Lu; Chiun Hsu; Yu-Yun Shao; Yee Chao; Chia-Jui Yen; I-Lun Shih; Yi-Ping Hung; Chun-Jung Chang; Ying-Chun Shen; Jhe-Cyuan Guo; Tsung-Hao Liu; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2019-08-06       Impact factor: 11.740

8.  Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.

Authors:  Matias Riihimäki; Hauke Thomsen; Akseli Hemminki; Kristina Sundquist; Kari Hemminki
Journal:  BMC Cancer       Date:  2013-01-28       Impact factor: 4.430

Review 9.  Role of lymphocytes in liver cancer.

Authors:  Jana C Mossanen; Frank Tacke
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

10.  Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.

Authors:  Ioannis Karydis; Pui Ying Chan; Matthew Wheater; Edurne Arriola; Peter W Szlosarek; Christian H Ottensmeier
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.